Fred Chasalow, Ph.D. earned his doctorate in biochemistry at Brandeis University and served as a post-doctoral fellow at ALZA, then as a Senior Research Associate at Columbia P&S (now Vagelos College of Physicians and Surgeons.) From 1977 to 1995, Dr. Chasalow served at several academic appointments, culminating as Professor of Pediatrics at SUNY, Brooklyn, and Chief of Pediatric Research at Maimonides Medical Center and Director of its Pediatric Endocrine Laboratory. During this period, much of his research included establishing diagnostic methods appropriate for small samples available from infants
In 1991, Dr. Chasalow was appointed as a member of the SuperGen Scientific Advisory Board and played a key role in their scientific development, leading to a successful IPO in 1996. His business experience includes some time as an Associate Vice President at Morgan Stanley and 15 years as an independent financial advisor. In 1995, Dr. Chasalow was one of the founders of AMUR Research. It was in his capacity as Chief Scientific Officer that Dr. Chasalow started the investigation that led to the discovery of three novel steroids. Later, AMUR was sold to SuperGen. In 2015, Dr. Chasalow founded IOMA LLC. At IOMA, Dr. Chasalow is credited with discovering three novel steroids.